In a report released yesterday, Jamie Stockton from Wells Fargo maintained a Buy rating on Evolent Health (EVH). The company’s shares closed yesterday at $14.67, close to its 52-week low of $13.61.
According to TipRanks.com, Stockton is ranked #1095 out of 5215 analysts.
Currently, the analyst consensus on Evolent Health is a Strong Buy with an average price target of $27, an 84.0% upside from current levels. In a report issued on February 19, Piper Jaffray also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29.05 and a one-year low of $13.61. Currently, Evolent Health has an average volume of 1.21M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolent Health, Inc. engages in the provision of health care delivery and payment services. Its solutions include population health management, health plan administration and third party administration, network performance management, risk adjustment, pharmacy benefit management, analytics and performance improvement, and technology and electronic medical record integration. The company was founded by Frank J. Williams, Seth B. Blackley, and Tom Peterson in August 2011 and is headquartered in Arlington, VA.
